Figure 3 | Scientific Reports

Figure 3

From: Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab

Figure 3The alternative text for this image may have been generated using AI.

Anti-PD-L1 mAb increases specific T cells in tumor, resulting in T cell-dependent antitumor activity in the PD-L1-negative tumor model. (A) Tumor volume of mice treated with anti-PD-L1 mAb along with CD8α mAb or CD4 mAb in the FM3A tumor model on Day 19 or Day14, respectively (n = 7/group). Data are shown as the mean + SD. Statistical analysis used Wilcoxon rank sum test and the Holm–Bonferroni method. *P < 0.05. (B) Infiltration of CD8α+ T cells into tumors was determined by CD8α immunohistochemical staining in tumor tissue after anti-PD-L1 mAb treatment (Day 19). (C) Percentage of T cells in tumor after anti-PD-L1 mAb treatment (Day 19) (n = 14/group). Cells were determined by flow cytometric analysis. Statistical analysis used Wilcoxon rank sum test. *P < 0.05. (D) Percentage of TCRα variable (TRAV) and TCRα joining (TRAJ) gene segments in tumor after anti-PD-L1 mAb treatment (Day 19). Next-generation sequencing was performed with unbiased TCR repertoire analysis technology (Repertoire Genesis). The inverse of Simpson’s diversity index was used to examine diversity based on the clonal dominance of each TCR clonotype (n = 3–5/group). Data are shown as the mean + SD.

Back to article page